<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4988042</article-id><article-id pub-id-type="publisher-id">664</article-id><article-id pub-id-type="doi">10.1186/s12883-016-0664-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Goselink</surname><given-names>Rianne J. M.</given-names></name><address><email>Rianne.Goselink@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schreuder</surname><given-names>Tim H. A.</given-names></name><address><email>Tim.Schreuder@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mul</surname><given-names>Karlien</given-names></name><address><email>Karlien.Mul@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Voermans</surname><given-names>Nicol C.</given-names></name><address><email>Nicol.Voermans@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pelsma</surname><given-names>Maaike</given-names></name><address><email>Maaike.Pelsma@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>de Groot</surname><given-names>Imelda J. M.</given-names></name><address><email>Imelda.deGroot@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Alfen</surname><given-names>Nens</given-names></name><address><email>Nens.vanAlfen@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Franck</surname><given-names>Bas</given-names></name><address><email>Bas.Franck@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Theelen</surname><given-names>Thomas</given-names></name><address><email>Thomas.Theelen@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lemmers</surname><given-names>Richard J.</given-names></name><address><email>R.J.L.F.Lemmers@lumc.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mah</surname><given-names>Jean K.</given-names></name><address><email>Jean.Mah@albertahealthservices.ca</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>van der Maarel</surname><given-names>Silv&#x000e8;re M.</given-names></name><address><email>S.M.van_der_Maarel@lumc.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>van Engelen</surname><given-names>Baziel G.</given-names></name><address><email>Baziel.vanEngelen@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Erasmus</surname><given-names>Corrie E.</given-names></name><address><email>Corrie.Erasmus@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Neurology, Donders Center for Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Rehabilitation, Donders Center for Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Clinical audiology, Radboud University Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff4"><label>4</label>Department of Op Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff5"><label>5</label>Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands </aff><aff id="Aff6"><label>6</label>Department of Paediatric Neurology, Alberta Children&#x02019;s Hospital, Calgary, Canada </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>138</elocation-id><history><date date-type="received"><day>18</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Facioscapulohumeral muscular dystrophy (FSHD; OMIM 158900 &#x00026; 158901) is a progressive skeletal muscle dystrophy, characterized by an autosomal dominant inheritance pattern. One of the major unsolved questions in FSHD is the marked clinical heterogeneity, ranging from asymptomatic individuals to severely affected patients with an early onset. An estimated 10&#x000a0;% of FSHD patients have an early onset (onset before 10&#x000a0;years of age) and are traditionally classified as infantile FSHD. This subgroup is regarded as severely affected and extra-muscular symptoms, such as hearing loss and retinopathy, are frequently described. However, information on the prevalence, natural history and clinical management of early onset FSHD is currently lacking, thereby hampering adequate patient counselling and management. Therefore, a population-based prospective cohort study on FSHD in children is highly needed.</p></sec><sec><title>Methods/design</title><p>This explorative study aims to recruit all children (aged 0&#x02013;17 years) with a genetically confirmed diagnosis of FSHD in The Netherlands. The children will be assessed at baseline and at 2-year follow-up. The general aim of the study is the description of the clinical features and genetic characteristics of this paediatric cohort. The primary outcome is the motor function as measured by the Motor Function Measure. Secondary outcomes include quantitative and qualitative description of the clinical phenotype, muscle imaging, genotyping and prevalence estimations. The ultimate objective will be a thorough description of the natural history, predictors of disease severity and quality of life in children with FSHD.</p></sec><sec><title>Discussion</title><p>The results of this population-based study are vital for adequate patient management and clinical trial-readiness. Furthermore, this study is expected to provide additional insight in the epigenetic and environmental disease modifying factors. In addition to improve counselling, this could contribute to unravelling the aetiology of FSHD.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02625662?term=fshd&#x00026;rank=23">NCT02625662</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Facioscapulohumeral dystrophy</kwd><kwd>Neuromuscular diseases</kwd><kwd>Muscular dystrophies</kwd><kwd>Paediatrics</kwd><kwd>Observational study</kwd></kwd-group><funding-group><award-group><funding-source><institution>Prinses Beatrix Spierfonds (NL)</institution></funding-source><award-id>WO.R14-22</award-id><principal-award-recipient><name><surname>Erasmus</surname><given-names>Corrie E.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Facioscapulohumeral dystrophy (FSHD) is a muscular dystrophy characterized by progressive weakness and atrophy of the facial (facio-), shoulder-upper arm (scapulohumeral-), axial- and leg muscles [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. FSHD is one of the most prevalent muscular dystrophies with an estimated prevalence of 12:100.000 [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>One of the hallmarks of FSHD is its clinical heterogeneity; the spectrum varies from severely affected, wheelchair bound children to asymptomatic carriers in late adulthood, even within families with the same repeat contraction [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Typically FSHD has an onset in adolescence and life expectancy is not impaired [<xref ref-type="bibr" rid="CR7">7</xref>]. However, a subgroup of patients has a childhood onset and is associated with more severe disease progression. FSHD is increasingly recognized as an epigenetic disease, which could be an explanation for this clinical heterogeneity.</p><sec id="Sec2"><title>Classification</title><p>Traditionally, children with very early onset have been classified as a distinct disease identity named <italic>infantile FSHD</italic> [<xref ref-type="bibr" rid="CR8">8</xref>], based on the following criteria [<xref ref-type="bibr" rid="CR9">9</xref>]:<list list-type="bullet"><list-item><p>signs or symptoms of facial weakness before the age of 5 and</p></list-item><list-item><p>signs or symptoms of scapular weakness before the age of 10</p></list-item></list></p><p>The concept of two FSHD types has gradually developed to an FSHD spectrum, with infantile onset being on the severe end and asymptomatic carriers on the other end. Accordingly, recent articles mostly classify the disease severity according to the repeat length of the genetic defect in FSHD1 [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, the correlation between disease severity and repeat length is inconsistent and is influenced by other genetic and environmental modifiers [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. A generally accepted definition of severely affected FSHD or early onset &#x0201c;classical&#x0201d; patients is currently lacking.</p></sec><sec id="Sec3"><title>Prevalence</title><p>Few studies have investigated the prevalence of childhood onset FSHD and these studies have used different selection criteria. Estimations of early onset FSHD vary between 3&#x02013;21&#x000a0;% of the total FSHD population [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and 58&#x000a0;% of the pediatric FSHD population (onset at any age&#x02009;&#x0003c;&#x02009;18&#x000a0;years [<xref ref-type="bibr" rid="CR17">17</xref>]). Accurate prevalence estimations of childhood onset FSHD are useful for interpretation of clinical studies, planning and increasing clinical trial-readiness.</p></sec><sec id="Sec4"><title>Extramuscular symptoms</title><p>Various extramuscular symptoms such as epilepsy, hearing difficulties, retinal abnormalities (Coats&#x02019; syndrome), mental retardation and cardiac arrhythmias are associated with FSHD and they are most frequently described in the early onset subgroup [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Little is known regarding the prevalence and aetiology of these extramuscular symptoms in children with FSHD. The current body of knowledge may be skewed by publication bias, selection bias and no/incorrect molecular diagnoses.</p></sec><sec id="Sec5"><title>Genetics</title><p>FSHD is increasingly recognized as an epigenetic disease. The most frequent cause of FSHD is contraction of the polymorphic D4Z4 macrosatellite repeat array in the subtelomere of chromosome 4 at 4q35 resulting in FSHD type 1 (FSHD1) [<xref ref-type="bibr" rid="CR20">20</xref>]. This mutation explains &#x0003e;95&#x000a0;% of the adult cases and all known infantile cases. Healthy individuals have 8 or more D4Z4 repeats on each 4q35 copy, whereas patients with FSHD1 have 1&#x02013;10 repeats on one copy of the 4q35 chromosome region and a disease-permissive allele 4A on the chromosome 4q subtelomere. In contrast to 4A alleles, 4B alleles, which lack a polyadenlylation signal for the <italic>DUX4</italic> gene which is embedded in each repeat of the D4Z4 array, are non-permissive to the disease [<xref ref-type="bibr" rid="CR21">21</xref>]. There is a copy of the D4Z4 repeat array on chromosome 10, but in absence of a DUX4 polyadenylation signal, contractions of this array are also not pathogenic [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>This causative genotype explains the variability in disease onset and progression only to some extent. The inverse correlation between residual repeat length and disease severity (short repeat lengths are associated with an earlier onset, wheelchair dependency and extramuscular involvement [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]) is imperfect; for example, it does not explain the intra-familial differences in phenotype. Aberrant epigenetic regulation of the D4Z4 chromatin structure is thought to play an important role in this clinical heterogeneity, and disruption of the 4q35 D4Z4 array chromatin structure in somatic cells is associated with all forms of FSHD [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. These epigenetic disruptions can be environmentally influenced and are important therapeutic targets. Epigenetic disruptions in FSHD include chromatin relaxation through the SMCHD1 or DNMT3B gene defect causing FSHD type 2 (FSHD2) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], hypomethylation [<xref ref-type="bibr" rid="CR14">14</xref>], alternative RNA splicing and nucleosome remodelling [<xref ref-type="bibr" rid="CR15">15</xref>]. Investigating novel (epi)genetic characteristics in children with FSHD and linking this genetic profile to disease severity and age at onset will contribute to better predictors of prognosis and understanding of the pathogenesis.</p></sec><sec id="Sec6"><title>Clinical management</title><p>A highly needed evidence-based guideline for the diagnosis and management of FSHD has recently been published [<xref ref-type="bibr" rid="CR28">28</xref>]. However, a specific guideline for children with FSHD and adult patients with early onset FSHD is currently lacking. Furthermore, adequate information on natural history and disease markers are important for clinical trial-preparedness [<xref ref-type="bibr" rid="CR29">29</xref>], with fast approaching therapeutic trials [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>In conclusion, data on the natural history, predictors and optimal clinical management of children with FSHD is limited. Thorough description of the clinical and genetic characteristics is vital for adequate management and could help to elucidate the underlying aetiology [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Here we describe the objectives and methods of this population-based, prospective, observational study on early onset FSHD.</p></sec></sec><sec id="Sec7"><title>Objectives</title><p>The primary objective of the study is:<list list-type="order"><list-item><p>to assess the clinical, genetic and epigenetic features of children with FSHD to optimize clinical management.</p><p>The secondary objectives are:</p></list-item><list-item><p>to define a new comprehensive definition of early onset FSHD;</p></list-item><list-item><p>to provide prevalence estimations of early onset FSHD in The Netherlands;</p></list-item><list-item><p>to establish a well-characterized baseline cohort for prospective follow-up and recruitment for future clinical trials;</p></list-item><list-item><p>to assess 2-year disease progression rate in children with FSHD and develop a prognostic model.</p></list-item></list></p></sec><sec id="Sec8"><title>Methods and design</title><sec id="Sec9"><title>Project design</title><p>The iFocus study is a prospective observational study performed at the department of paediatric Neurology of the Radboud University Medical Center, The Netherlands; it is a tertiary referral center for neuromuscular diseases. Genetic and epigenetic studies will be performed in the department of Human Genetics of the Leiden University Medical Center, The Netherlands. Participation in the study will not affect the usual care provided by the patients&#x02019; own medical team.</p></sec><sec id="Sec10"><title>Study population</title><p>Eligible patients are children aged 0&#x02013;17 years with symptoms of facioscapulohumeral dystrophy and genetically proven FSHD1 or FSHD2 living in The Netherlands. Exclusion criteria are: inability or unwillingness to provide informed consent. The aim is to include all children in The Netherlands with a genetically confirmed diagnosis of FSHD. We expect to include 20&#x02013;30 patients based on the estimated prevalence in the population [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>There is no agreement on the classification of children with FSHD. Therefore we chose to include all patients less than 18&#x000a0;years with genetically confirmed FSHD, including for example children with isolated hearing loss as well. This enables us to describe the complete spectrum of children with FSHD. In addition, this study could identify predictors of severity and prognosis, thereby serving as a reference for working towards a widely accepted classification.</p></sec><sec id="Sec11"><title>Recruitment and screening</title><p>Participants will be recruited non-selectively and consecutively in the period from November 2015-November 2016. In order to estimate the prevalence of FSHD in children, we will try to reach all children with FSHD in The Netherlands through a very intensive recruitment. All Dutch paediatric neurologists, paediatricians and specialized paediatric physiotherapists will be personally asked about potential participants. In addition, all patients registered at the Dutch neuromuscular patient association [<xref ref-type="bibr" rid="CR34">34</xref>] and the databases CRAMP [<xref ref-type="bibr" rid="CR35">35</xref>] and Focus (NL48204.091.14) will be personally informed. Thirdly, we will directly recruit participants through promotion of our study on patient information days, patient websites and social media.</p><p>In order to provide data on the complete spectrum of children with FSHD we aim to identify all children with clinically suspected FSHD, with or without genetic confirmation of FSHD. For this study we defined clinically suspected FSHD as: clinical weakness of the facial and/or upper-arm muscles for which the patient sought medical attention with exclusion of other diagnoses. For the children without genetic confirmation there are two scenarios:<list list-type="order"><list-item><p>Patients with clinically suspected FSHD and an FSHD-affected family member. Patients will be included in the study and genetic tests will be performed after obtaining informed consent.</p></list-item><list-item><p>Children with clinically suspected FSHD without an FSHD-affected family member will be invited for a pre-inclusion screening. This pre-screening will involve clinical examination by two of the authors (CE and RG). If FSHD is clinically highly suspected, the patient will be counselled for further assessments (i.e. genetic testing and referral to a specialized childhood neurologist for further rehabilitation care). If the diagnosis is genetically confirmed, the patient can be included in the study. If clinical suspicion is low or the genetic testing is negative, the children will not be included in the study and will be referred back to their treating medical staff (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of inclusion</p></caption><graphic xlink:href="12883_2016_664_Fig1_HTML" id="MO1"/></fig></p></list-item></list></p></sec><sec id="Sec12"><title>Assessments</title><p>Participants will be invited for a baseline visit at the department of paediatric neurology at the Radboud University Medical Center. If the patient is unable to visit the hospital, the patient is offered a home visit and auditory, ophthalmologic and ultrasonography procedures will be omitted. Patients will have a follow-up visit after 2&#x000a0;years.</p></sec><sec id="Sec13"><title>Demographics</title><p>Date of birth, sex, weight (Kg), height (m) and medication will be recorded. Clinical characteristics of both parents will be directly examined and the genealogy of 3 consecutive generations will be drawn. The growth curves and medical history and medication use will be registered.</p></sec><sec id="Sec14"><title>Outcome measures</title><p>The outcome measures are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and are structured according to the format of the International Classification of Functioning, Disability and Health for children and youth (ICF-CY [<xref ref-type="bibr" rid="CR36">36</xref>]). The ICF is the World Health Organization framework for measuring health and disability at both individual and population levels and is subdivided in body functions, body structures, activities and participation and environmental factors. All procedures will be assessed at baseline visit and after 2-year follow-up if not otherwise specified.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Outcome measures and tests at baseline and follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Outcome domain</th><th>Tests</th><th>Age</th></tr></thead><tbody><tr><td colspan="3">Primary outcome measure</td></tr><tr><td colspan="3">&#x02003;ICF: Activities and participation</td></tr><tr><td>&#x02003;&#x02003;Motor function</td><td>Motor Function Measure [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]</td><td>2&#x02013;18</td></tr><tr><td colspan="3">Secondary outcome measures</td></tr><tr><td colspan="3">&#x02003;ICF: body functions</td></tr><tr><td rowspan="3">&#x02003;&#x02003;Mental functions</td><td>Education level (school level)</td><td>5&#x02013;18</td></tr><tr><td>EEG [<xref ref-type="bibr" rid="CR48">48</xref>]<sup>a</sup>
</td><td>0&#x02013;18</td></tr><tr><td>Denver II developmental screening test [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>0&#x02013;6</td></tr><tr><td>&#x02003;&#x02003;Seeing functions</td><td>Visual acuity (Snellen)</td><td>4&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Hearing functions</td><td>Tone- and speech audiometry</td><td>2&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Pain</td><td>Faces scale pain [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>6&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Cardiac function</td><td>ECG [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>0&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Aerobic exercise tolerance</td><td>6-minute walk test MWT [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]</td><td>walk</td></tr><tr><td>&#x02003;&#x02003;Fatigability</td><td>NeuroQol fatigue domain [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td>2&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Respiratory function</td><td>Forced vital capacity and forced expiratory volume Spirometry [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td>6&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Digestive, defecation, weight maintenance and urination functions</td><td>Qualitative history</td><td>0&#x02013;18</td></tr><tr><td rowspan="3">&#x02003;&#x02003;Ingestion functions</td><td>TOMASS-C test [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>6&#x02013;18</td></tr><tr><td>Neuromuscular disease swallowing status scale [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td>2&#x02013;18</td></tr><tr><td>Dysphagia questionnaire [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]</td><td>2&#x02013;18</td></tr><tr><td rowspan="5">&#x02003;&#x02003;Muscle functions</td><td>Handgrip dynamometer</td><td>6&#x02013;18</td></tr><tr><td>Manual muscle testing [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td>0&#x02013;18</td></tr><tr><td>Serum creatine kinase (CK)</td><td>0&#x02013;18</td></tr><tr><td>Age-adjusted clinical severity scale [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]</td><td>5&#x02013;18</td></tr><tr><td>FSHD evaluation score [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td/></tr><tr><td colspan="3">&#x02003;ICF: Body structure</td></tr><tr><td rowspan="3">&#x02003;&#x02003;Eye structure</td><td>Slit lamp examination</td><td>4&#x02013;18</td></tr><tr><td>Dilated fundoscopy</td><td>4&#x02013;18</td></tr><tr><td>Optical coherence angiography tomography</td><td>6&#x02013;18</td></tr><tr><td rowspan="2">&#x02003;&#x02003;Movement related structures</td><td>Muscle ultrasonography [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td>0&#x02013;18</td></tr><tr><td>Spine x-ray<sup>a</sup>
</td><td>4&#x02013;18</td></tr><tr><td colspan="3">&#x02003;ICF: Activities and participation</td></tr><tr><td>&#x02003;&#x02003;Communication/social interactions</td><td>Social Economic Questionnaire SEV [<xref ref-type="bibr" rid="CR63">63</xref>]<sup>a</sup>
</td><td>4&#x02013;18</td></tr><tr><td>&#x02003;&#x02003;Self-care/life areas</td><td>Kidscreen [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td>8&#x02013;18</td></tr><tr><td colspan="3">&#x02003;ICF: Environmental factors</td></tr><tr><td>&#x02003;&#x02003;Products and natural environment</td><td>Qualitative anamnesis and history</td><td>0&#x02013;18</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup> Only if clinically indicated</p></table-wrap-foot></table-wrap></p><p>Outcome measures are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and are extensive due to the explorative character of the study. The primary outcome is the motor function as measured by the Motor Function Measure [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. This measure specifically includes axial and upper limb functions, is designed for both ambulatory and non-ambulatory patients and can be continued into adulthood. Motor performance is supplementary assessed using the 6&#x000a0;min walking test, handgrip dynamometer and manual muscle testing MRC-scores. The FSHD evaluation score and the age-adjusted clinical severity scale are scored to explore the validity of these scales in children. In addition, non-muscular symptoms are extensively tested based on earlier literature on childhood onset FSHD [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Quantitative muscle ultrasonography (QMUS) will be used to screen for muscle myopathy/inflammation. QMUS is a patient-friendly non-invasive method to screen for dystrophic changes in skeletal muscle [<xref ref-type="bibr" rid="CR39">39</xref>]. The technique has been well-validated for screening and follow-up in several childhood and adult neuromuscular disorders [<xref ref-type="bibr" rid="CR40">40</xref>]. The following muscles will be measured on both sides, using a fixed scanning protocol and settings as previously described [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]: depressor anguli oris, masseter, sternocleidomastoideus, biceps brachii, rectus abdominis, rectus femoris, gastrocnemicus and tibialis anterior [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p>Extramuscular symptoms will be assessed based on symptoms as reported in literature. This will include an extensive ophthalmologic screening, including optical coherence tomography with angiography for specific focus on the retinal arteries [<xref ref-type="bibr" rid="CR45">45</xref>], a tone- and speech audiometry, electrocardiogram (ECG) and spirometry. Electro-encephalography (EEG) and spinal x-ray will be performed if indicated.</p><sec id="Sec15"><title>Prevalence</title><p>An improvement of the prevalence estimations will be assessed by comparing our recruitment with anonymous data of the genetic testing by the Leiden University Medical Center, where all Dutch samples are tested. This method is based on earlier research in the adult population [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec16"><title>(Epi)genetic disease-modifying factors</title><p>To explore the relationship between (epi)genetic disease-modifying factors and the disease severity, an extensive qualitative history is taken. Focus is on medical history (traumata, infections), dietary intake and maternal and perinatal health, including maternal substance use.</p><p>From participants and biological parents (if available) high molecular weight DNA and RNA will be isolated from peripheral blood mononucleated cell (PBMCs). The sizing of the D4Z4 repeats on chromosomes 4 and 10 will be executed using pulsed field gel electrophoresis (PFGE) and the haplotype analysis by hybridization of PFGE blots with probes A and B in combination with PCR-based SSLP analysis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Methylation of the D4Z4 repeat will be established at the FseI restriction site in the proximal unit of the D4Z4 array [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In case of reduced CpG methylation at D4Z4, gene mutations in SMCHD1 or DNMT3B will be analysed by Sanger sequencing and predicted splice site mutations or nonsense mutations will be further analysed using cDNA isolated from PBMCs.</p><p>For RNA isolation from PBMCs we use PAXgene Blood RNA tubes which will be processed for obtaining high quality RNA for whole genome RNA sequencing analysis (RNAseq).</p></sec><sec id="Sec17"><title>Cohort for future trial acquisition</title><p>An additional goal of this study is to obtain a well-documented cohort for longer (&#x0003e;2&#x000a0;years) follow-up and future trial acquisition. Patients will be asked to participate in the Dutch FSHD registration study [<xref ref-type="bibr" rid="CR46">46</xref>] and for biomaterial storage. Serum samples of the participant and both biological parents will be stored in the Radboud biobank (<ext-link ext-link-type="uri" xlink:href="http://www.radboudbiobank.nl/nl/">http://www.radboudbiobank.nl/nl/</ext-link>) and are available for future DNA and/or RNA research for researchers worldwide.</p></sec></sec><sec id="Sec18"><title>Data collection</title><p>All parents/legal guardians of participants will receive an online form with the standardized questionnaires. All participants&#x02009;&#x0003e;&#x02009;8&#x000a0;years will also receive an online form with the standardized questionnaires for children. The forms will be sent through Castor and directly stored in the Castor database (Version 2015, [<xref ref-type="bibr" rid="CR47">47</xref>]). All data-management and data-monitoring will be performed within the Castor software.</p></sec><sec id="Sec19"><title>Statistics</title><p>The Statistical Package for the Social Sciences (SPSS version 22, IBM, Armonk, New York) will be used to conduct all statistical analyses. Due to the explorative nature of the iFocus study, descriptive statistics will be applied to describe all patient characteristics. Continuous data are described as mean&#x02009;&#x000b1;&#x02009;standard deviations. If reference values are available from literature, we will check for overlapping confidence intervals. Number of non-missing values is described (missing data are not replaced) unless stated otherwise. For describing the D4Z4 CpG methylation corrected repeat size, the delta 1 score will be used [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Correlations between (novel) molecular markers and clinical severity will be assessed with Spearman rank correlation. Possible correlations will be assessed on the following variables: &#x02018;corrected repeat length&#x02019;, &#x02018;age at investigation&#x02019;, &#x02018;hereditary pattern&#x02019; &#x02018;age at onset&#x02019;, various extramuscular symptoms, FSHD severity score and motor function measurement scores. If novel (molecular) variables are found, these will be added in the statistical model. To minimize the multicolinearity manual backward reduction will be executed.</p><p>For the clinical prediction model, multiple linear regressions will be used to explore the relationship between potential disease modifying variables and disease severity. In addition, for the 2&#x000a0;year follow-up data, linear mixed models will be applied for analysis of differences in disease progression. The primary outcome is a continuous variable, FSHD clinical severity score. The fixed effect predictors are repeat length (divided in 1&#x02013;3 D4Z4 repeat units (U), 4&#x02013;6 U and 7&#x02013;10 U), current age, hereditary pattern and sex.</p></sec><sec id="Sec20"><title>Time plan</title><p>Patients will be included in 2016 and follow-up visits will be scheduled in 2018. The first results are expected at the end of 2018.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p>Results from the iFocus study will provide insights into the clinical and genetic spectrum of children with FSHD. These insights are vital for adequate symptomatic management and clinical trial-readiness. We propose extensive qualitative and quantitative measurements specified by age and use a modified format of the International Classification of Functioning, Disability and Health criteria. This structured approach enables us to give an explorative, full-spectrum, unbiased clinical description of FSHD in children.</p><p>Furthermore, this study aims to provide additional insight in the epigenetic and environmental disease modifying factors. This could help to unravel the aetiology of FSHD and serve as a basis for prognostic and therapeutic models.</p><p>One of the study&#x02019;s strengths is the excellent recruitment organisation in The Netherlands, thereby reducing selection bias. There is a well-organized health system with free access to paediatric neurology for every child. In addition, our centers have a longstanding history of excellent FSHD research and administration. Finally, all participants can reach the study center within three hours. These assets make it possible to execute a population based, nation-wide study.</p><p>A critical issue is the small number of participants, making it hard to verify correlations or differences in subgroups, international collaborations are in preparation. Although, we expect to find differences in motor functioning after 2 years of follow-up, this period will possibly be too short for changes in other outcome measures such as wheelchair dependency. Therefore we aim to continue the follow-up of this cohort for a longer period of time.</p><p>In conclusion, the iFocus study is expected to yield new knowledge on children with FSHD, aiming to optimize clinical management, help unravelling the aetiology of FSHD and serve as a basis for prognostic and therapeutic studies.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DNA</term><def><p>Deoxyribonucleic acid</p></def></def-item><def-item><term>DNMT3B</term><def><p>DNA methyltransferase 3B</p></def></def-item><def-item><term>FSHD</term><def><p>Facioscapulohumeral muscular dystrophy</p></def></def-item><def-item><term>ICF-Y</term><def><p>The International Classification of Functioning, Disability and Health for children and youth</p></def></def-item><def-item><term>MFM</term><def><p>Motor Function Measure</p></def></def-item><def-item><term>MRC</term><def><p>Medical Research Council</p></def></def-item><def-item><term>PBMC</term><def><p>Peripheral blood mononucleated cell</p></def></def-item><def-item><term>PFGE</term><def><p>Pulsed field gel electrophoresis</p></def></def-item><def-item><term>RNA</term><def><p>Ribonucleic acid</p></def></def-item><def-item><term>SMCHD1</term><def><p>Structural maintenance of chromosomes flexible hinge domain containing 1</p></def></def-item><def-item><term>U</term><def><p>D4Z4 repeat unit</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organisation</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We would like to thank all patients and parents for their time and effort in this study. In addition we would like to acknowledge the following people who have contributed to the study: Herjan Bavelaar, Hanneke Deenen, Yvonne Dominicus, Lenie van den Engel-Hoek, Annet Geerlings, Merel Jansen, Janine Meeuwsen-Schilp, Kees Okkersen, Wiebe Pestman, Anouke van Rumund, Bas Stunnenberg, Inge Vos, Tessa Wassenberg and Jack Weeda.</p><sec id="FPar1"><title>Funding</title><p>This study is funded with a competitively awarded, peer-reviewed grant from the Dutch Neuromuscular Fund (Prinses Beatrix Spierfonds). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Prinses Beatrix Spierfonds.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets which will be collected during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>All authors have read and approved the final manuscript. RG contributed to the design of the study, data collection and project planning and led the drafting and revising of the manuscript, including medical writing for content. TS contributed to the study design, drafting and revising of the manuscript for content, including medical writing for content. KM contributed to drafting and revising of the manuscript for content, to the study concept or design and patient selection. IG, NV, MP, NA, BF and TT contributed to drafting and revising of the manuscript for content and to the study concept or design. RL en SM contributed to drafting and revising of the manuscript for content, to the study concept or design and genetic design, technical support and providing supervision. BE contributed to the drafting and revising of the manuscript for content, including medical writing for content, to the study concept or design, to obtaining funds and providing supervision. CE contributed to the study design, drafting and revising of the manuscript for content, including medical writing for content, patient selection, obtaining funds and providing supervision. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>This study protocol has been approved by the Medical Review Ethics Committee region Arnhem-Nijmegen (NL53213.091.15). Signed informed consent will be obtained from participants aged 12&#x02013;18 years and from parents/legal guardians of all participants.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Padberg</surname><given-names>GW</given-names></name></person-group><source>Facioscapulohumeral dystrophy</source><year>1982</year></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Van Der Maarel</surname><given-names>SM</given-names></name></person-group><article-title>Facioscapulohumeral muscular dystrophy</article-title><source>Muscle Nerve</source><year>2006</year><volume>34</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/mus.20522</pub-id><?supplied-pmid 16508966?><pub-id pub-id-type="pmid">16508966</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG. What&#x02019;s in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol. 2016;16(3):201&#x02013;7. doi:10.1136/practneurol-2015-001353. Epub 2016 Feb 9. Review.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deenen</surname><given-names>JC</given-names></name><name><surname>Arnts</surname><given-names>H</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>Verschuuren</surname><given-names>JJ</given-names></name><name><surname>Bakker</surname><given-names>E</given-names></name><name><surname>Weinreich</surname><given-names>SS</given-names></name><name><surname>Verbeek</surname><given-names>AL</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name></person-group><article-title>Population-based incidence and prevalence of facioscapulohumeral dystrophy</article-title><source>Neurology</source><year>2014</year><volume>83</volume><issue>12</issue><fpage>1056</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000797</pub-id><?supplied-pmid 25122204?><pub-id pub-id-type="pmid">25122204</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaillard</surname><given-names>MC</given-names></name><name><surname>Roche</surname><given-names>S</given-names></name><name><surname>Dion</surname><given-names>C</given-names></name><name><surname>Tasmadjian</surname><given-names>A</given-names></name><name><surname>Bouget</surname><given-names>G</given-names></name><name><surname>Salort-Campana</surname><given-names>E</given-names></name><name><surname>Vovan</surname><given-names>C</given-names></name><name><surname>Chaix</surname><given-names>C</given-names></name><name><surname>Broucqsault</surname><given-names>N</given-names></name><name><surname>Morere</surname><given-names>J</given-names></name><etal/></person-group><article-title>Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers</article-title><source>Neurology</source><year>2014</year><volume>83</volume><issue>8</issue><fpage>733</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000708</pub-id><?supplied-pmid 25031281?><pub-id pub-id-type="pmid">25031281</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonini</surname><given-names>MM</given-names></name><name><surname>Pavanello</surname><given-names>RC</given-names></name><name><surname>Gurgel-Giannetti</surname><given-names>J</given-names></name><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Zatz</surname><given-names>M</given-names></name></person-group><article-title>Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><issue>2</issue><fpage>e17</fpage><pub-id pub-id-type="doi">10.1136/jmg.2003.010637</pub-id><?supplied-pmid 14757867?><pub-id pub-id-type="pmid">14757867</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>JLF</given-names></name><name><surname>Lemmers</surname><given-names>P</given-names></name><name><surname>Daniel</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>MD</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name></person-group><source>Facioscapulohumeral Muscular Dystrophy</source><year>2014</year></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooke</surname><given-names>MH</given-names></name></person-group><article-title>Clinical examination of patients with neuromuscular disease</article-title><source>Adv Neurol</source><year>1977</year><volume>17</volume><fpage>25</fpage><lpage>39</lpage><?supplied-pmid 888738?><pub-id pub-id-type="pmid">888738</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>OF</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name></person-group><article-title>Facioscapulohumeral muscular dystrophy in early childhood</article-title><source>Arch Neurol</source><year>1994</year><volume>51</volume><issue>4</issue><fpage>387</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1001/archneur.1994.00540160085011</pub-id><?supplied-pmid 8155016?><pub-id pub-id-type="pmid">8155016</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevisan</surname><given-names>CP</given-names></name><name><surname>Pastorello</surname><given-names>E</given-names></name><name><surname>Tomelleri</surname><given-names>G</given-names></name><name><surname>Vercelli</surname><given-names>L</given-names></name><name><surname>Bruno</surname><given-names>C</given-names></name><name><surname>Scapolan</surname><given-names>S</given-names></name><name><surname>Siciliano</surname><given-names>G</given-names></name><name><surname>Comacchio</surname><given-names>F</given-names></name></person-group><article-title>Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions</article-title><source>Eur J Neurol</source><year>2008</year><volume>15</volume><issue>12</issue><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02314.x</pub-id><?supplied-pmid 19049553?><pub-id pub-id-type="pmid">19049553</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Lai</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>PL</given-names></name><name><surname>Hsu</surname><given-names>JH</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>YK</given-names></name><name><surname>Nishino</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>CW</given-names></name><name><surname>Shih</surname><given-names>HH</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment</article-title><source>Neuromuscul Disord</source><year>2013</year><volume>23</volume><issue>4</issue><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2013.01.005</pub-id><?supplied-pmid 23434070?><pub-id pub-id-type="pmid">23434070</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolic</surname><given-names>A</given-names></name><name><surname>Ricci</surname><given-names>G</given-names></name><name><surname>Sera</surname><given-names>F</given-names></name><name><surname>Bucci</surname><given-names>E</given-names></name><name><surname>Govi</surname><given-names>M</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Ruggiero</surname><given-names>L</given-names></name><name><surname>Vercelli</surname><given-names>L</given-names></name><name><surname>Ravaglia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>e007798</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2015-007798</pub-id><?supplied-pmid 26733561?><pub-id pub-id-type="pmid">26733561</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacconi</surname><given-names>S</given-names></name><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>Balog</surname><given-names>J</given-names></name><name><surname>van der Vliet</surname><given-names>PJ</given-names></name><name><surname>Lahaut</surname><given-names>P</given-names></name><name><surname>van Nieuwenhuizen</surname><given-names>MP</given-names></name><name><surname>Straasheijm</surname><given-names>KR</given-names></name><name><surname>Debipersad</surname><given-names>RD</given-names></name><name><surname>Vos-Versteeg</surname><given-names>M</given-names></name><name><surname>Salviati</surname><given-names>L</given-names></name><etal/></person-group><article-title>The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1</article-title><source>Am J Hum Genet</source><year>2013</year><volume>93</volume><issue>4</issue><fpage>744</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2013.08.004</pub-id><?supplied-pmid 24075187?><pub-id pub-id-type="pmid">24075187</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>Goeman</surname><given-names>JJ</given-names></name><name><surname>van der Vliet</surname><given-names>PJ</given-names></name><name><surname>van Nieuwenhuizen</surname><given-names>MP</given-names></name><name><surname>Balog</surname><given-names>J</given-names></name><name><surname>Vos-Versteeg</surname><given-names>M</given-names></name><name><surname>Camano</surname><given-names>P</given-names></name><name><surname>Ramos Arroyo</surname><given-names>MA</given-names></name><name><surname>Jerico</surname><given-names>I</given-names></name><name><surname>Rogers</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2</article-title><source>Hum Mol Genet</source><year>2015</year><volume>24</volume><issue>3</issue><fpage>659</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu486</pub-id><?supplied-pmid 25256356?><pub-id pub-id-type="pmid">25256356</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himeda</surname><given-names>CL</given-names></name><name><surname>Debarnot</surname><given-names>C</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Beermann</surname><given-names>ML</given-names></name><name><surname>Miller</surname><given-names>JB</given-names></name><name><surname>Jones</surname><given-names>PL</given-names></name><name><surname>Jones</surname><given-names>TI</given-names></name></person-group><article-title>Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene</article-title><source>Mol Cell Biol</source><year>2014</year><volume>34</volume><issue>11</issue><fpage>1942</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1128/MCB.00149-14</pub-id><?supplied-pmid 24636994?><pub-id pub-id-type="pmid">24636994</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorobek</surname><given-names>M</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>Ryniewicz</surname><given-names>B</given-names></name><name><surname>Kabzinska</surname><given-names>D</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Gawel</surname><given-names>M</given-names></name><name><surname>Walecki</surname><given-names>J</given-names></name><name><surname>Hausmanowa-Petrusewicz</surname><given-names>I</given-names></name></person-group><article-title>Early-onset facioscapulohumeral muscular dystrophy type 1 with some atypical features</article-title><source>J Child Neurol</source><year>2015</year><volume>30</volume><issue>5</issue><fpage>580</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1177/0883073814528281</pub-id><?supplied-pmid 24717985?><pub-id pub-id-type="pmid">24717985</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinge</surname><given-names>L</given-names></name><name><surname>Eagle</surname><given-names>M</given-names></name><name><surname>Haggerty</surname><given-names>ID</given-names></name><name><surname>Roberts</surname><given-names>CE</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Bushby</surname><given-names>KM</given-names></name></person-group><article-title>Severe phenotype in infantile facioscapulohumeral muscular dystrophy</article-title><source>Neuromuscul Disord</source><year>2006</year><volume>16</volume><issue>9-10</issue><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2006.06.008</pub-id><?supplied-pmid 16934468?><pub-id pub-id-type="pmid">16934468</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funakoshi</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Arahata</surname><given-names>K</given-names></name></person-group><article-title>Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy</article-title><source>Neurology</source><year>1998</year><volume>50</volume><issue>6</issue><fpage>1791</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1212/WNL.50.6.1791</pub-id><?supplied-pmid 9633729?><pub-id pub-id-type="pmid">9633729</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>KL</given-names></name><name><surname>Holte</surname><given-names>L</given-names></name><name><surname>Kliethermes</surname><given-names>SA</given-names></name><name><surname>Stephan</surname><given-names>C</given-names></name><name><surname>Mathews</surname><given-names>KD</given-names></name></person-group><article-title>Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy</article-title><source>Neurology</source><year>2013</year><volume>81</volume><issue>16</issue><fpage>1374</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a84140</pub-id><?supplied-pmid 24042093?><pub-id pub-id-type="pmid">24042093</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Brouwer</surname><given-names>OF</given-names></name><name><surname>Moerer</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>JL</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name></person-group><article-title>Location of facioscapulohumeral muscular dystrophy gene on chromosome 4</article-title><source>Lancet</source><year>1990</year><volume>336</volume><issue>8716</issue><fpage>651</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(90)92148-B</pub-id><?supplied-pmid 1975852?><pub-id pub-id-type="pmid">1975852</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>de Kievit</surname><given-names>P</given-names></name><name><surname>Sandkuijl</surname><given-names>L</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name></person-group><article-title>Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><issue>2</issue><fpage>235</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/ng999</pub-id><?supplied-pmid 12355084?><pub-id pub-id-type="pmid">12355084</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>van der Vliet</surname><given-names>PJ</given-names></name><name><surname>Klooster</surname><given-names>R</given-names></name><name><surname>Sacconi</surname><given-names>S</given-names></name><name><surname>Camano</surname><given-names>P</given-names></name><name><surname>Dauwerse</surname><given-names>JG</given-names></name><name><surname>Snider</surname><given-names>L</given-names></name><name><surname>Straasheijm</surname><given-names>KR</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><etal/></person-group><article-title>A unifying genetic model for facioscapulohumeral muscular dystrophy</article-title><source>Science</source><year>2010</year><volume>329</volume><issue>5999</issue><fpage>1650</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1126/science.1189044</pub-id><?supplied-pmid 20724583?><pub-id pub-id-type="pmid">20724583</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunt</surname><given-names>PW</given-names></name><name><surname>Jardine</surname><given-names>PE</given-names></name><name><surname>Koch</surname><given-names>MC</given-names></name><name><surname>Maynard</surname><given-names>J</given-names></name><name><surname>Osborn</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Upadhyaya</surname><given-names>M</given-names></name></person-group><article-title>Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD)</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><issue>5</issue><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1093/hmg/4.5.951</pub-id><?supplied-pmid 7633457?><pub-id pub-id-type="pmid">7633457</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Forrester</surname><given-names>J</given-names></name><name><surname>Griggs</surname><given-names>RC</given-names></name><name><surname>Mendell</surname><given-names>J</given-names></name><name><surname>Kissel</surname><given-names>J</given-names></name><name><surname>McDermott</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>W</given-names></name><name><surname>Weiffenbach</surname><given-names>B</given-names></name><name><surname>Figlewicz</surname><given-names>D</given-names></name></person-group><article-title>Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group</article-title><source>Ann Neurol</source><year>1996</year><volume>39</volume><issue>6</issue><fpage>744</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1002/ana.410390610</pub-id><?supplied-pmid 8651646?><pub-id pub-id-type="pmid">8651646</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himeda</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>TI</given-names></name><name><surname>Jones</surname><given-names>PL</given-names></name></person-group><article-title>Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease</article-title><source>Antioxid Redox Signal</source><year>2015</year><volume>22</volume><issue>16</issue><fpage>1463</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1089/ars.2014.6090</pub-id><?supplied-pmid 25336259?><pub-id pub-id-type="pmid">25336259</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Overveld</surname><given-names>PG</given-names></name><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>Sandkuijl</surname><given-names>LA</given-names></name><name><surname>Enthoven</surname><given-names>L</given-names></name><name><surname>Winokur</surname><given-names>ST</given-names></name><name><surname>Bakels</surname><given-names>F</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name></person-group><article-title>Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy</article-title><source>Nat Genet</source><year>2003</year><volume>35</volume><issue>4</issue><fpage>315</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/ng1262</pub-id><?supplied-pmid 14634647?><pub-id pub-id-type="pmid">14634647</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmers</surname><given-names>RJ</given-names></name><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Petek</surname><given-names>LM</given-names></name><name><surname>Balog</surname><given-names>J</given-names></name><name><surname>Block</surname><given-names>GJ</given-names></name><name><surname>Santen</surname><given-names>GW</given-names></name><name><surname>Amell</surname><given-names>AM</given-names></name><name><surname>van der Vliet</surname><given-names>PJ</given-names></name><name><surname>Almomani</surname><given-names>R</given-names></name><name><surname>Straasheijm</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><issue>12</issue><fpage>1370</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1038/ng.2454</pub-id><?supplied-pmid 23143600?><pub-id pub-id-type="pmid">23143600</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Kissel</surname><given-names>JT</given-names></name><name><surname>Heatwole</surname><given-names>C</given-names></name><name><surname>Pandya</surname><given-names>S</given-names></name><name><surname>Gronseth</surname><given-names>G</given-names></name><name><surname>Benatar</surname><given-names>M</given-names></name><collab>Guideline Development D, Implementation Subcommittee of the American Academy of N, Practice Issues Review Panel of the American Association of N, Electrodiagnostic M</collab></person-group><article-title>Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &#x00026; Electrodiagnostic Medicine</article-title><source>Neurology</source><year>2015</year><volume>85</volume><issue>4</issue><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001783</pub-id><?supplied-pmid 26215877?><pub-id pub-id-type="pmid">26215877</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>Shaw</surname><given-names>DW</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Participants</surname><given-names>FW</given-names></name></person-group><article-title>Clinical trial preparedness in facioscapulohumeral muscular dystrophy: Clinical, tissue, and imaging outcome measures 29-30 May 2015, Rochester, New York</article-title><source>Neuromuscul Disord</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2015.10.005</pub-id><?supplied-pmid 26627872?><pub-id pub-id-type="pmid">26627872</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passerieux</surname><given-names>E</given-names></name><name><surname>Hayot</surname><given-names>M</given-names></name><name><surname>Jaussent</surname><given-names>A</given-names></name><name><surname>Carnac</surname><given-names>G</given-names></name><name><surname>Gouzi</surname><given-names>F</given-names></name><name><surname>Pillard</surname><given-names>F</given-names></name><name><surname>Picot</surname><given-names>MC</given-names></name><name><surname>Bocker</surname><given-names>K</given-names></name><name><surname>Hugon</surname><given-names>G</given-names></name><name><surname>Pincemail</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial</article-title><source>Free Radic Biol Med</source><year>2015</year><volume>81</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.09.014</pub-id><?supplied-pmid 25246239?><pub-id pub-id-type="pmid">25246239</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voet</surname><given-names>N</given-names></name><name><surname>Bleijenberg</surname><given-names>G</given-names></name><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>de Groot</surname><given-names>I</given-names></name><name><surname>Padberg</surname><given-names>G</given-names></name><name><surname>van Engelen</surname><given-names>B</given-names></name><name><surname>Geurts</surname><given-names>A</given-names></name></person-group><article-title>Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD: an RCT</article-title><source>Neurology</source><year>2014</year><volume>83</volume><issue>21</issue><fpage>1914</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001008</pub-id><?supplied-pmid 25339206?><pub-id pub-id-type="pmid">25339206</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Blackburn K. In<italic>.</italic>; 2016: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02603562">https://clinicaltrials.gov/ct2/show/NCT02603562</ext-link>.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name></person-group><article-title>Facioscapulohumeral dystrophy: the path to consensus on pathophysiology</article-title><source>Skelet Muscle</source><year>2014</year><volume>4</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/2044-5040-4-12</pub-id><?supplied-pmid 24940479?><pub-id pub-id-type="pmid">24940479</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Spierziekten Nederland [<ext-link ext-link-type="uri" xlink:href="https://www.spierziekten.nl/over-ons/">https://www.spierziekten.nl/over-ons/</ext-link>]. Accessed 8 Nov 2016.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>van Veenendaal</surname><given-names>H</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>Faber</surname><given-names>CG</given-names></name><name><surname>van der Hoeven</surname><given-names>JH</given-names></name><name><surname>Janssen</surname><given-names>NG</given-names></name><name><surname>Notermans</surname><given-names>NC</given-names></name><name><surname>van Schaik</surname><given-names>IN</given-names></name><name><surname>Visser</surname><given-names>LH</given-names></name><name><surname>Verschuuren</surname><given-names>JJ</given-names></name></person-group><article-title>The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): development and preliminary data</article-title><source>Neuromuscul Disord</source><year>2007</year><volume>17</volume><issue>1</issue><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2006.09.017</pub-id><?supplied-pmid 17141501?><pub-id pub-id-type="pmid">17141501</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>ICF : International classification of functioning, disability and health / World Health Organization</source><year>2015</year></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berard</surname><given-names>C</given-names></name><name><surname>Payan</surname><given-names>C</given-names></name><name><surname>Hodgkinson</surname><given-names>I</given-names></name><name><surname>Fermanian</surname><given-names>J</given-names></name><collab>Group MFMCS</collab></person-group><article-title>A motor function measure for neuromuscular diseases. Construction and validation study</article-title><source>Neuromuscul Disord</source><year>2005</year><volume>15</volume><issue>7</issue><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2005.03.004</pub-id><?supplied-pmid 16106528?><pub-id pub-id-type="pmid">16106528</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lattre</surname><given-names>C</given-names></name><name><surname>Payan</surname><given-names>C</given-names></name><name><surname>Vuillerot</surname><given-names>C</given-names></name><name><surname>Rippert</surname><given-names>P</given-names></name><name><surname>de Castro</surname><given-names>D</given-names></name><name><surname>Berard</surname><given-names>C</given-names></name><name><surname>Poirot</surname><given-names>I</given-names></name><name><surname>Group</surname><given-names>MFMS</given-names></name></person-group><article-title>Motor function measure: validation of a short form for young children with neuromuscular diseases</article-title><source>Arch Phys Med Rehabil</source><year>2013</year><volume>94</volume><issue>11</issue><fpage>2218</fpage><lpage>2226</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2013.04.001</pub-id><?supplied-pmid 23602884?><pub-id pub-id-type="pmid">23602884</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Pillen S, Verrips A, van Alfen N, Arts IM, Sie LT, Zwarts MJ. Quantitative skeletal muscle ultrasound: diagnostic value in childhood neuromuscular disease. Neuromuscul Disord. NMD 2007;17(7):509&#x02013;16. Epub 2007 May 29.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Engel-Hoek</surname><given-names>L</given-names></name><name><surname>Erasmus</surname><given-names>CE</given-names></name><name><surname>Hendriks</surname><given-names>JC</given-names></name><name><surname>Geurts</surname><given-names>AC</given-names></name><name><surname>Klein</surname><given-names>WM</given-names></name><name><surname>Pillen</surname><given-names>S</given-names></name><name><surname>Sie</surname><given-names>LT</given-names></name><name><surname>de Swart</surname><given-names>BJ</given-names></name><name><surname>de Groot</surname><given-names>IJ</given-names></name></person-group><article-title>Oral muscles are progressively affected in Duchenne muscular dystrophy: implications for dysphagia treatment</article-title><source>J Neurol</source><year>2013</year><volume>260</volume><issue>5</issue><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1007/s00415-012-6793-y</pub-id><?supplied-pmid 23263593?><pub-id pub-id-type="pmid">23263593</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>BH</given-names></name><name><surname>Pillen</surname><given-names>S</given-names></name><name><surname>Voet</surname><given-names>NB</given-names></name><name><surname>Heerschap</surname><given-names>A</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>van Alfen</surname><given-names>N</given-names></name></person-group><article-title>Quantitative muscle ultrasound versus quantitative magnetic resonance imaging in facioscapulohumeral dystrophy</article-title><source>Muscle Nerve</source><year>2014</year><volume>50</volume><issue>6</issue><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1002/mus.24247</pub-id><?supplied-pmid 24659533?><pub-id pub-id-type="pmid">24659533</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfen</surname><given-names>NV</given-names></name><name><surname>Gilhuis</surname><given-names>HJ</given-names></name><name><surname>Keijzers</surname><given-names>JP</given-names></name><name><surname>Pillen</surname><given-names>S</given-names></name><name><surname>Van Dijk</surname><given-names>JP</given-names></name></person-group><article-title>Quantitative facial muscle ultrasound: feasibility and reproducibility</article-title><source>Muscle Nerve</source><year>2013</year><volume>48</volume><issue>3</issue><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/mus.23769</pub-id><?supplied-pmid 23893891?><pub-id pub-id-type="pmid">23893891</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>BH</given-names></name><name><surname>Voet</surname><given-names>NB</given-names></name><name><surname>Nabuurs</surname><given-names>CI</given-names></name><name><surname>Kan</surname><given-names>HE</given-names></name><name><surname>de Rooy</surname><given-names>JW</given-names></name><name><surname>Geurts</surname><given-names>AC</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>Heerschap</surname><given-names>A</given-names></name></person-group><article-title>Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e85416</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0085416</pub-id><?supplied-pmid 24454861?><pub-id pub-id-type="pmid">24454861</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Monforte</surname><given-names>M</given-names></name><name><surname>Iannaccone</surname><given-names>E</given-names></name><name><surname>Laschena</surname><given-names>F</given-names></name><name><surname>Ottaviani</surname><given-names>P</given-names></name><name><surname>Leoncini</surname><given-names>E</given-names></name><name><surname>Boccia</surname><given-names>S</given-names></name><name><surname>Galluzzi</surname><given-names>G</given-names></name><name><surname>Pelliccioni</surname><given-names>M</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Upper girdle imaging in facioscapulohumeral muscular dystrophy</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e100292</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0100292</pub-id><?supplied-pmid 24932477?><pub-id pub-id-type="pmid">24932477</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Statland</surname><given-names>JM</given-names></name><name><surname>Sacconi</surname><given-names>S</given-names></name><name><surname>Farmakidis</surname><given-names>C</given-names></name><name><surname>Donlin-Smith</surname><given-names>CM</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Tawil</surname><given-names>R</given-names></name></person-group><article-title>Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size</article-title><source>Neurology</source><year>2013</year><volume>80</volume><issue>13</issue><fpage>1247</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182897116</pub-id><?supplied-pmid 23446679?><pub-id pub-id-type="pmid">23446679</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Deenen JC. In. <ext-link ext-link-type="uri" xlink:href="http://www.fshdregistratie.nl/">http://www.fshdregistratie.nl/</ext-link>. Accessed 8 Dec 2016.</mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">CastorEDC [<ext-link ext-link-type="uri" xlink:href="https://castoredc.com/">https://castoredc.com/</ext-link>]</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Davignon AP RE, Boisselle F. Normal ECG standards for infants and children. Pediatr Cardiol. 1979;1:123&#x02013;31.</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankenburg</surname><given-names>WK</given-names></name><name><surname>Dodds</surname><given-names>J</given-names></name><name><surname>Archer</surname><given-names>P</given-names></name><name><surname>Shapiro</surname><given-names>H</given-names></name><name><surname>Bresnick</surname><given-names>B</given-names></name></person-group><article-title>The Denver II: a major revision and restandardization of the Denver Developmental Screening Test</article-title><source>Pediatrics</source><year>1992</year><volume>89</volume><issue>1</issue><fpage>91</fpage><lpage>97</lpage><?supplied-pmid 1370185?><pub-id pub-id-type="pmid">1370185</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>CL</given-names></name><name><surname>von Baeyer</surname><given-names>CL</given-names></name><name><surname>Spafford</surname><given-names>PA</given-names></name><name><surname>van Korlaar</surname><given-names>I</given-names></name><name><surname>Goodenough</surname><given-names>B</given-names></name></person-group><article-title>The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement</article-title><source>Pain</source><year>2001</year><volume>93</volume><issue>2</issue><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(01)00314-1</pub-id><?supplied-pmid 11427329?><pub-id pub-id-type="pmid">11427329</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>GP</given-names></name><name><surname>van der Kooi</surname><given-names>E</given-names></name><name><surname>Behin</surname><given-names>A</given-names></name><name><surname>Smeets</surname><given-names>J</given-names></name><name><surname>Timmermans</surname><given-names>J</given-names></name><name><surname>van der Maarel</surname><given-names>S</given-names></name><name><surname>Padberg</surname><given-names>G</given-names></name><name><surname>Voermans</surname><given-names>N</given-names></name><name><surname>van Engelen</surname><given-names>B</given-names></name></person-group><article-title>High prevalence of incomplete right bundle branch block in facioscapulohumeral muscular dystrophy without cardiac symptoms</article-title><source>Funct Neurol</source><year>2014</year><volume>29</volume><issue>3</issue><fpage>159</fpage><lpage>165</lpage><?supplied-pmid 25473735?><pub-id pub-id-type="pmid">25473735</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Laboratories ATSCoPSfCPF</collab></person-group><article-title>ATS statement: guidelines for the six-minute walk test</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>1</issue><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.166.1.at1102</pub-id><pub-id pub-id-type="pmid">12091180</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>CM</given-names></name><name><surname>Henricson</surname><given-names>EK</given-names></name><name><surname>Han</surname><given-names>JJ</given-names></name><name><surname>Abresch</surname><given-names>RT</given-names></name><name><surname>Nicorici</surname><given-names>A</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Atkinson</surname><given-names>L</given-names></name><name><surname>Reha</surname><given-names>A</given-names></name><name><surname>Hirawat</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy</article-title><source>Muscle Nerve</source><year>2010</year><volume>41</volume><issue>4</issue><fpage>500</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1002/mus.21544</pub-id><?supplied-pmid 19941337?><pub-id pub-id-type="pmid">19941337</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordijn</surname><given-names>M</given-names></name><name><surname>Cremers</surname><given-names>EM</given-names></name><name><surname>Kaspers</surname><given-names>GJ</given-names></name><name><surname>Gemke</surname><given-names>RJ</given-names></name></person-group><article-title>Fatigue in children: reliability and validity of the Dutch PedsQL Multidimensional Fatigue Scale</article-title><source>Qual Life Res</source><year>2011</year><volume>20</volume><issue>7</issue><fpage>1103</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1007/s11136-010-9836-9</pub-id><?supplied-pmid 21246290?><pub-id pub-id-type="pmid">21246290</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jat</surname><given-names>KR</given-names></name></person-group><article-title>Spirometry in children</article-title><source>Prim Care Respir J</source><year>2013</year><volume>22</volume><issue>2</issue><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.4104/pcrj.2013.00042</pub-id><?supplied-pmid 23732636?><pub-id pub-id-type="pmid">23732636</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Huckabee</surname><given-names>ML</given-names></name><name><surname>McIntosh</surname><given-names>T</given-names></name><name><surname>Apperley</surname><given-names>O</given-names></name></person-group><source>Quantitative Assessment of Oral Phase Efficiency: TOMASS Norms and Preliminary Validation</source><year>2014</year><publisher-loc>Nashville, TN, USA</publisher-loc><publisher-name>Dysphagia Research Society Annual Scientific Meeting, 5-8 Mar 2014</publisher-name></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Wada A, Kawakami M, Liu M, Otaka E, Nishimura A, Liu F, Otsuka T. Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS). J Neurol. 2015.</mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Engel-Hoek</surname><given-names>L</given-names></name><name><surname>Erasmus</surname><given-names>CE</given-names></name><name><surname>van Bruggen</surname><given-names>HW</given-names></name><name><surname>de Swart</surname><given-names>BJ</given-names></name><name><surname>Sie</surname><given-names>LT</given-names></name><name><surname>Steenks</surname><given-names>MH</given-names></name><name><surname>de Groot</surname><given-names>IJ</given-names></name></person-group><article-title>Dysphagia in spinal muscular atrophy type II: more than a bulbar problem?</article-title><source>Neurology</source><year>2009</year><volume>73</volume><issue>21</issue><fpage>1787</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c34aa6</pub-id><?supplied-pmid 19933981?><pub-id pub-id-type="pmid">19933981</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhoutte</surname><given-names>EK</given-names></name><name><surname>Faber</surname><given-names>CG</given-names></name><name><surname>van Nes</surname><given-names>SI</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>van Koningsveld</surname><given-names>R</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><name><surname>van der Kooi</surname><given-names>AJ</given-names></name><name><surname>Cats</surname><given-names>EA</given-names></name><name><surname>van den Berg</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Modifying the Medical Research Council grading system through Rasch analyses</article-title><source>Brain</source><year>2012</year><volume>135</volume><issue>Pt 5</issue><fpage>1639</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1093/brain/awr318</pub-id><?supplied-pmid 22189568?><pub-id pub-id-type="pmid">22189568</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Galluzzi</surname><given-names>G</given-names></name><name><surname>Deidda</surname><given-names>G</given-names></name><name><surname>Cacurri</surname><given-names>S</given-names></name><name><surname>Colantoni</surname><given-names>L</given-names></name><name><surname>Merico</surname><given-names>B</given-names></name><name><surname>Piazzo</surname><given-names>N</given-names></name><name><surname>Servidei</surname><given-names>S</given-names></name><name><surname>Vigneti</surname><given-names>E</given-names></name><name><surname>Pasceri</surname><given-names>V</given-names></name><etal/></person-group><article-title>Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><issue>6</issue><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199906)45:6&#x0003c;751::AID-ANA9&#x0003e;3.0.CO;2-M</pub-id><?supplied-pmid 10360767?><pub-id pub-id-type="pmid">10360767</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Overveld</surname><given-names>PG</given-names></name><name><surname>Enthoven</surname><given-names>L</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Felicetti</surname><given-names>L</given-names></name><name><surname>Jeanpierre</surname><given-names>M</given-names></name><name><surname>Winokur</surname><given-names>ST</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name></person-group><article-title>Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy</article-title><source>Ann Neurol</source><year>2005</year><volume>58</volume><issue>4</issue><fpage>569</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1002/ana.20625</pub-id><?supplied-pmid 16178028?><pub-id pub-id-type="pmid">16178028</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamperti</surname><given-names>C</given-names></name><name><surname>Fabbri</surname><given-names>G</given-names></name><name><surname>Vercelli</surname><given-names>L</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>R</given-names></name><name><surname>Frusciante</surname><given-names>R</given-names></name><name><surname>Bonifazi</surname><given-names>E</given-names></name><name><surname>Fiorillo</surname><given-names>C</given-names></name><name><surname>Borsato</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Servida</surname><given-names>M</given-names></name><etal/></person-group><article-title>A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: the FSHD clinical score</article-title><source>Muscle Nerve</source><year>2010</year><volume>42</volume><issue>2</issue><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1002/mus.21671</pub-id><?supplied-pmid 20544930?><pub-id pub-id-type="pmid">20544930</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Ploeg PDEMSePDJDvd: Sociaal-Emotionele Vragenlijst (SEV): Houten: Springer Media; 2015. <ext-link ext-link-type="uri" xlink:href="http://www.testweb.bsl.nl/tests/sev/">http://www.testweb.bsl.nl/tests/sev/</ext-link>.</mixed-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravens-Sieberer</surname><given-names>U</given-names></name><name><surname>Gosch</surname><given-names>A</given-names></name><name><surname>Rajmil</surname><given-names>L</given-names></name><name><surname>Erhart</surname><given-names>M</given-names></name><name><surname>Bruil</surname><given-names>J</given-names></name><name><surname>Duer</surname><given-names>W</given-names></name><name><surname>Auquier</surname><given-names>P</given-names></name><name><surname>Power</surname><given-names>M</given-names></name><name><surname>Abel</surname><given-names>T</given-names></name><name><surname>Czemy</surname><given-names>L</given-names></name><etal/></person-group><article-title>KIDSCREEN-52 quality-of-life measure for children and adolescents</article-title><source>Expert Rev Pharmacoecon Outcomes Res</source><year>2005</year><volume>5</volume><issue>3</issue><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1586/14737167.5.3.353</pub-id><?supplied-pmid 19807604?><pub-id pub-id-type="pmid">19807604</pub-id></element-citation></ref></ref-list></back></article>